Liberty Latin America Azioni (NASDAQ: LILA)

Ultime notizie per Liberty Latin America (NASDAQ:LILA) Azioni

Liberty Latin America

Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.

Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)&nbsp;has agreed to combine its Biosciences &amp; Diagnostic Solutions business with Waters Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>).
The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026.
<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Biosciences segment</a> offers immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments, reagents, and multiomics tools.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years" target="_blank" rel="noreferrer noopener">Becton Dickinson Vitals Drop: Analysts &#8216;Have Been Wrong&#8217; On This Med Tech Stock For Years</a>
Diagnostic Solutions offers microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation, and point-of-care offerings.
For calendar year 2025, BD&#8217;s Biosciences &amp; Diagnostic Solutions business is expected to generate revenue of approximately&nbsp;$3.4 billion&nbsp;and adjusted EBITDA of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46387499/waters-and-bds-biosciences-diagnostic-solutions-business-to-combine-creating-a-life-science-and-di" rel="noreferrer noopener">approximately&nbsp;$925 million</a>.
<h2 class="wp-block-heading">Financial Benefits</h2>
The transaction is expected to create approximately&nbsp;$200 million&nbsp;of cost synergies by year three post-closing, and approximately&nbsp;$290 million&nbsp;of revenue synergies by year five, resulting in approximately&nbsp;$345 million&nbsp;of annualized EBITDA synergies by 2030.
Cost synergies are expected to be driven primarily by manufacturing, supply chain, and SG&amp;A optimization while maintaining a strong commitment to R&amp;D and commercial investments.
Revenue synergies are expected from commercial excellence, accelerating expansion into high-growth adjacencies, and realizing cross-selling opportunities.
The combined company is expected to generate pro forma revenue of approximately&nbsp;$6.5 billion&nbsp;and approximately&nbsp;$2.0 billion&nbsp;in pro forma adjusted EBITDA for calendar year 2025.
On a pro forma basis, the combination is expected to deliver mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth on an annualized basis between 2025 and 2030.
By 2030, the pro forma combined company is expected to have an industry-leading financial outlook with approximately&nbsp;$9 billion&nbsp;in revenue,&nbsp;$3.3 billion&nbsp;in adjusted EBITDA, and an adjusted operating margin of 32%.
The transaction is expected to be accretive to adjusted EPS in the first year post-closing.
Commenting on the transaction, Flemming Ornskov, Chairman, Waters, said, &#8220;This transaction marks a pivotal milestone in Waters&#8217; transformation journey as we embark on a new chapter of growth and value creation. As the Board of Directors evaluated this opportunity throughout the process, it became evident that combining with BD&#8217;s Biosciences &amp; Diagnostic Solutions business is an excellent strategic fit with complementary strengths. We are confident that this combination will accelerate our strategy in multiple high-growth markets and deliver substantial near- and long-term value to our shareholders.&#8221;
BD&#8217;s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8%. BD will also receive a cash distribution of approximately $4 billion before completion of the combination.
Waters is expected to assume approximately&nbsp;$4 billion&nbsp;of incremental debt, resulting in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing.
Price Action: WAT stock was down 5.07% at $335, and BDX stock was down 0.84% at $174.50 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46386582/elon-musk-wants-tesla-to-invest-in-xai-but-its-up-to-shareholders-this-analyst-says-grok-is-worth-the-bet" target="_blank" rel="noreferrer noopener">Elon Musk Wants Tesla To Invest In xAI, But It&#8217;s Up To Shareholders: This Analyst Says Grok Is Worth The Bet</a></li>
</ul>
Photo via Shutterstock

Large Cap

News

Health Care

Movers

General

Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger

VBTX

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Keybanc analyst Scott Schoenhaus maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and lowers the price target from $106 to $93.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Eastman Chemical, Lowers Price Target to $93

Barclays analyst Saket Kalia maintains Gen Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) with a Equal-Weight and raises the price target from $30 to $32.

Barclays Maintains Equal-Weight on Gen Digital, Raises Price Target to $32

WIIM

SQNS

Sequans shares are trading higher after the company announced it bought 683 more Bitcoins and provided updates on its total holdings.

Keybanc analyst Scott Schoenhaus maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Overweight and raises the price target from $65 to $70.

DOCS

Keybanc Maintains Overweight on Doximity, Raises Price Target to $70

NCNO

NCino shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $30 to $38.

Keybanc analyst Aleksey Yefremov maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $85 to $87.

Keybanc Maintains Overweight on DuPont de Nemours, Raises Price Target to $87

Barclays analyst Saket Kalia maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Equal-Weight and raises the price target from $103 to $110.

FTNT

Barclays Maintains Equal-Weight on Fortinet, Raises Price Target to $110

CRWD

CrowdStrike Holdings shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.

Cryptocurrency markets are off to a blazing start on Monday morning, with Bitcoin making a new all-time high above $123,000.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$121,812.36</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,070.88</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$167.48</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.99</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2069</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001383</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction decreased by 14.7% and 7.9%, respectively. Daily active addresses dropped by 5.6% and 3.6%, respectively.</li>
<li>Coinglass data shows129,769 traders were liquidated in the past 24 hours for $750.05 million.</li>
<li>SoSoValue data shows net inflows of $1.03 billion into spot Bitcoin ETFs on Friday. Spot Ethereum ETFs saw net inflows of $204.8 million.</li>
</ul>
Trader Notes: CoinBureau co-founder Nic Puckrin <a href="https://x.com/nicrypto/status/1944645969556963392">highlighted</a> the importance of Bitcoin breaching a 7-year-long monthly resistance trendline, which acted as the ceiling in past bull markets dating back to 2018.
Rekt Capital <a href="https://x.com/rektcapital/status/1944697759107281211">says</a> a convincing breakout above $124,000 would open the floodgates for Bitcoin, triggering rapid price discovery with little resistance above.
Michael van de Poppe forecasts rising volatility, with sharp dips likely to be absorbed quickly. He believes the next major leg to $250,000 has begun, projecting $150,000 by Q3.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There we go. A massive impulse on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> as it&#39;s at $122K. What to expect? Volatility has been going up, so we will be having severe corrections which are going to be quickly bought up. The upwards move to $250K has started. $150K in Q3. <a href="https://t.co/ixSbObm24u">pic.twitter.com/ixSbObm24u</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1944669726828826928?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cryptoinsightuk <a href="https://x.com/Cryptoinsightuk/status/1944688049851363545">explained</a> that a break above $3.00 for XRP could unlock a move to all-time highs and initiate price discovery. The current price action is pressing against the final major resistance.
Crypto trader Jelle <a href="https://x.com/CryptoJelleNL/status/1944642366998012320">noted</a> Ethereum finally broke above the $2,800 resistance, flipping it into support. With momentum now shifting upward, the next key target is $4,000, as minimal resistance remains in that zone.
Jelle <a href="https://x.com/CryptoJelleNL/status/1944676843077964034">shared</a> a bold outlook, stating $600 is the long-term target for SOL, as the broader market rally gains traction.
Crypto trader CW pointed out that DOGE has broken its first sell wall and is approaching the next resistance zone between $0.24–$0.26, signaling further upside potential.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> is breaking the first sell wall. The next sell wall is $0.24-$0.26. <a href="https://t.co/jIc0qVwbDf">pic.twitter.com/jIc0qVwbDf</a>
&mdash; CW (@CW8900) <a href="https://twitter.com/CW8900/status/1944638939899326683?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46387048/bitcoin-is-humanitys-best-bet-against-currency-debasement-says-anthony-pompliano-we-owe-so-much-to-satoshi-nakamoto">Bitcoin Is Humanity&#8217;s &#8216;Best Bet&#8217; Against Currency Debasement, Says Anthony Pompliano: &#8216;We Owe So Much To Satoshi Nakamoto&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Why Are Bitcoin, Ethereum, XRP, Dogecoin Suddenly Skyrocketing?

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fvsee.como&amp;esheet=54289531&amp;newsitemid=20250714034916&amp;lan=en-US&amp;anchor=VSee+Health%2C+Inc.&amp;index=1&amp;md5=589aac8d6e07e263f1a9587e1a62a9a5">VSee Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) a leading provider of secure digital health solutions, today announced the launch of its new AI doctor notes, one of the solutions in its AI solutions suite.
VSee has partnered with Tele911, the largest national telemedicine emergency room diversion service, to integrate VSee's AI Doctor Notes into its virtual emergency care workflow. Emergency medicine demands rapid decision-making and high patient throughput. The integration has drastically reduced Tele911 physician's charting time by 93% from 15 minutes per visit to under 1 minute, potentially increasing physician visit capacity.
This new VSee AI solution automatically transcribes visits and generates structured SOAP notes with ICD codes in two clicks, allowing Tele911 physicians to reclaim valuable time. Now, instead of manual documentation, clinicians can focus on patient care.

Biotech

VSEE

VSee Launches AI Doctor Notes, Cutting Tele911 Physician Charting Time By 93% From 15 Minutes Per Visit To Under 1 Minute, Boosting Emergency Care Efficiency

Barclays analyst Saket Kalia maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Overweight and raises the price target from $405 to $440.

CYBR

Barclays Maintains Overweight on CyberArk Software, Raises Price Target to $440

Barclays analyst Saket Kalia maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Equal-Weight and raises the price target from $230 to $245.

CHKP

Barclays Maintains Equal-Weight on Check Point Software, Raises Price Target to $245

New material combines true silicone performance with precision 3D printing to meet demanding needs in automotive, healthcare, consumer goods, and industrial sectors
Stratasys Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) today announced the commercial launch of P3&#x2122; Silicone 25A, a high-performance material developed through a strategic collaboration with Shin-Etsu, a global leader in silicone science. Designed exclusively for the Stratasys Origin&#xAE; DLP platform, this general-purpose silicone enables production of flexible parts that match the performance of traditionally molded silicone.

SSYS

Stratasys Announces Commercial Launch Of P3 Silicone 25A, Developed Through Strategic Collaboration With Shin-Etsu

Barclays analyst Kannan Venkateshwar maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Underweight and raises the price target from $320 to $341.

CHTR

Barclays Maintains Underweight on Charter Communications, Raises Price Target to $341

Ocean Power Technologies, Inc. (NYSE:<a href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it has achieved ISO 9001 certification for its quality management system.
ISO 9001 is the world's most recognized quality management standard, awarded to organizations that consistently provide products and services that meet customer and regulatory requirements. This milestone affirms OPT's commitment to excellence in engineering, manufacturing, and service delivery across its product portfolio, including the PowerBuoy&#xAE;, WAM-V&#xAE; Unmanned Surface Vehicles, and its Merrows&#x2122; Maritime Domain Awareness Solution.

OPTT

Ocean Power Technologies Achieves ISO 9001 Certification, Underscoring Commitment To Quality In Marine Power And Data Solutions

Top Win International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SORA#NASDAQ">SORA</a>) has partnered with Simon Gerovich (CEO of Metaplanet) and KCGI, a leading Korea-based investment firm, for a planned investment in SGA Co., Ltd. (KOSDAQ:049470). SGA Co., Ltd., has filed with the regulators disclosing that its board of directors has approved a third-party share issuance to the said consortium of investors.
Upon completion, the investor group will become SGA's largest shareholder. Proceeds from the issuance will be used for strategic asset acquisitions and general corporate purposes. SGA Co., Ltd. plans to pursue new initiatives in the digital asset space by leveraging the consortium's global network and expertise, while continuing to operate its core business in close collaboration with affiliates across the SGA Group. As of the date hereof, parties are negotiating the terms of such investment and no definitive agreement has been signed with respect to such transaction.

Contracts

SORA

Top Win, Metaplanet CEO Simon Gerovich And KCGI Plan Investment To Become Largest Shareholder Of SGA Co., Ltd.; Plans To Pursue New Initiatives In The Digital Asset Space

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell sharply in <a href="https://www.benzinga.com/quote/RARE">pre-market trading</a>.
Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo Syndrome Type A (MPS IIIA).
Ultragenyx Pharmaceutical shares dipped 8% to $27.15 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares tumbled 31% to $44.25 in pre-market trading. MiNK Therapeutics shares jumped 730% on Friday after the company announced a publication in Oncogene.</li>
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) shares dipped 21.3% to $2.84 in pre-market trading after jumping 134% on Friday. Above Food Ingredients recently announced a merger agreement with Palm Global.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) declined 11.3% to $43.66 in pre-market trading after gaining 71% on Friday.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares dipped 11% to $3.08 in pre-market trading after declining 8% on Friday. CEL-SCI recently announced it signed a partnership with a Saudi Arabian pharma and healthcare company.</li>
<li>Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) slipped 8% to $11.13 in pre-market trading after gaining 39% on Friday.</li>
<li>Gossamer Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) declined 6.6% to $1.2700 in pre-market trading. Gossamer Bio, last month, completed enrollment in its registrational Phase 3 PROSERA study for pulmonary arterial hypertension</li>
<li>Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) fell 4.1% to $7.22 in pre-market trading. Gilat Satellite Networks recently announced its commercial division received over $22 million in orders from satellite operators.</li>
<li>KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) dipped 4% to $13.94 in pre-market trading after falling 6% on Friday. KalVista Pharma recently posted a wider-than-expected quarterly loss.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 1% to $209.22 in pre-market trading. Apple is in the midst of a significant management reshuffle. Despite the company's biggest crisis in years, CEO Tim Cook remains firmly at the helm.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

AAPL

ABVE

GILT

GOSS

INKT

KALV

NEGG

RARE

UMAC

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Barclays analyst Benjamin Budish maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and lowers the price target from $1220 to $1210.

Barclays Maintains Overweight on BlackRock, Lowers Price Target to $1210

Press Releases

LIBERTY LATIN AMERICA GIVES BACK TO COMMUNITIES ACROSS LATIN AMERICA AND THE CARIBBEAN DURING ANNUAL 'MISSION WEEK'

LIBERTY LATIN AMERICA'S C&W CREDIT SILO PRICES NEW $1.5 BILLION TERM LOAN DUE 2032

LIBERTY LATIN AMERICA'S C&W CREDIT SILO COMPLETES REFINANCING PROGRAM; ISSUES NEW $755 MILLION SENIOR NOTES DUE 2033

LIBERTY LATIN AMERICA SUPPORTS COMMUNITIES WITH RESOURCES TO ADOPT SAFER INTERNET PRACTICES

LIBERTY LATIN AMERICA SCHEDULES INVESTOR CALL FOR FULL-YEAR 2024 RESULTS

Liberty Latin America Reports Q4 and FY 2024 Results

LIBERTY LATIN AMERICA ANNOUNCES SOOMIT DATTA AS VP, INVESTOR RELATIONS

Liberty Latin America Taps CSG to Rocket Wholesale Growth to New Heights

LIBERTY LATIN AMERICA SCHEDULES INVESTOR CALL FOR FIRST QUARTER 2025 RESULTS

Liberty Latin America Reports Q1 2025 Results

CSGS

LILA

LILAB

LILAK

AST SpaceMobile, Inc. - Class A Common Stock

AST SpaceMobile

Anterix

Bandwidth

Cogent Communications Holdings, Inc. - Common Stock

Cogent Comms Hldgs

Globalstar

iOThree

iQSTEL

Iridium Communications Inc - Common Stock

Iridium Communications

Liberty Global Ltd. - Class A Common Shares

Liberty Global

Liberty Global Ltd. - Class C Common Shares

Liberty Latin America Ltd. - Class A Common Stock

Liberty Latin America Ltd. - Class C Common Stock

Lumen Technologies

NextPlat

Sify Technologies Limited - American Depository Shares, each represented by one Equity Share

Comments

Liberty Latin America

Notizie

Ultime notizie per Liberty Latin America (NASDAQ:LILA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO